$INO

Schall Law Firm files securities fraud class action against $INO for allegedly making false statements about manufacturing deficiencies and regulatory filing timelines.

Class action lawsuit filed against $INO for allegedly false statements about INO-3107 treatment and CELLECTRA device. Lead plaintiff deadline is April 7, 2026.

Pomerantz files class action against Inovio Pharmaceuticals for alleged securities fraud related to false FDA approval statements and concealed manufacturing deficiencies.

Levi & Korsinsky files class action against Inovio Pharmaceuticals alleging management misrepresented FDA accelerated approval eligibility for lead candidate, causing stock decline.

Rosen Law Firm notifies Inovio investors of securities class action with April 7, 2026 lead plaintiff deadline, citing alleged false statements on manufacturing and regulatory matters.

Inovio Pharmaceuticals faces class action lawsuit over alleged false statements regarding manufacturing defects and regulatory prospects after FDA rejected accelerated approval, causing 24% stock decline.

Four major companies face securities fraud lawsuits for misleading investors on AI spending, financial disclosures, and manufacturing claims. Investor filing deadlines approaching.

Inovio Pharmaceuticals faces FDA rejection of its lead drug candidate and mounting cash constraints, raising questions about the biotech firm's long-term viability without revenue-generating products.

Rosen Law Firm sues Enphase Energy for allegedly misrepresenting inventory management and overstating financial outlook regarding tax credit impacts.

Inovio Pharmaceuticals faces securities lawsuit alleging false statements about its CELLECTRA device and regulatory prospects. Investors who purchased stock between October 2023-December 2025 may qualify for compensation.

Rosen Law Firm files class action lawsuit against Inovio Pharmaceuticals for allegedly misrepresenting manufacturing capabilities and overstating product development prospects, urging investors to act before deadline.

Rosen Law Firm sues PomDoctor Ltd. for stock promotion fraud and misleading statements. Investors must act by April 7, 2026 deadline to join the class action.

Class action lawsuit filed against Inovio Pharmaceuticals for allegedly making false statements about device manufacturing capabilities and regulatory timelines between October 2023 and December 2025.

Schall Law Firm launches class action against Inovio Pharmaceuticals for alleged misrepresentations about manufacturing capabilities and regulatory timelines. Investors can join until April 7, 2026.

Rosen Law Firm sues Inovio Pharmaceuticals for allegedly making false statements about manufacturing capabilities and regulatory timelines, causing investor losses through inflated stock prices.

Endeavor Group Holdings faces securities lawsuit over alleged false merger disclosures regarding share valuation, executive pay, and conflicts of interest. Lead plaintiff deadline: March 18, 2026.

Rosen Law Firm filed a securities class action against Plug Power for alleged false statements about DOE funding and hydrogen facility construction. April 3, 2026 deadline for claimants.

Rosen Law Firm files securities class action against Inovio Pharmaceuticals for allegedly making false statements about manufacturing deficiencies and regulatory prospects between October 2023 and December 2025.

Inovio Pharmaceuticals faces securities lawsuit over false statements about manufacturing and regulatory prospects. FDA rejected accelerated approval for lead drug candidate, causing 24% stock drop.

Inovio Pharmaceuticals faces class action lawsuit for allegedly misleading investors about device manufacturing capabilities and regulatory delays, leading to 24% stock decline.